Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women of 30 years and older
By C. Meijer, Johannes Berkhof, P. Castle, A. Hesselink, E. Franco, G. Ronco, M. Arbyn, F. Bosch, Jack Cuzick, J. Dillner and 2 more. International Journal of Cancer, 2009
684 citations recorded by the source corpus.
Given the strong etiologic link between high‐risk HPV infection and cervical cancer high‐risk HPV testing is now being considered as an alternative for cytology‐based cervical cancer screening. Many test systems have been developed that can detect the broad spectrum of hrHPV types in one assay. However, for screening purposes the detection of high‐risk HPV is not inherently useful unless it is informative for the presence of high‐grade cervical intraepithelial neoplasia (CIN 2/3) or cancer. Candidate high‐risk HPV tests to be used for screening should reach an optimal balance between clinical sensitivity and specificity for detection of high‐grade CIN and cervical cancer to minimize redundant or excessive follow‐up procedures for high‐risk HPV positive women without cervical lesions. Data from various large screening studies have shown that high‐risk HPV testing by hybrid capture 2 and GP5+/6+‐PCR yields considerably better results in the detection of CIN 2/3 than cytology. The data from these studies can be used to guide the translation of high‐risk HPV testing into clinical practice by setting standards of test performance and characteristics. On the basis of these data we have developed guidelines for high‐risk HPV test requirements for primary cervical screening and validation guidelines for candidate HPV assays. © 2008 Wiley‐Liss, Inc.
Subfields: Epidemiology, Surgery
View Paper: https://www.semanticscholar.org/paper/2b7d46ebf1e64039ef942c9902431a076fda1545
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. (2012, background): “The equivalence crieria based on relative cross-sectional accuracy [4] are not valid or other molecular markers (for instance over-expressed proteins r viral RNA).”
- The molecular biology of head and neck cancer (2011, background): “These assays can detect only a few copies of viral DNA, and may detect not only the oncogenic infections, but also productive infections, virions or laboratory artefacts, problems well known from cervical cancer screening by HPV testin”
- American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. (2012, neutral): “For use in the United States, HPV tests should both be FDA approved (for validity) and meet specific criteria for clinical performance as described above.(47,48) Other well-validated tests (eg, GP5þ/6þ polymerase chain reaction-enzyme immunoassay) are commercially available in Europe, and data using”